Table 1.
Relationship between NEIL3 expression and clinicopathology in the TCGA LUAD cohort
| Characteristics | n | NEIL3 | χ2 | P value | |
|---|---|---|---|---|---|
| Low expression | High expression | ||||
| Total | 293 | 147 | 146 | ||
| Age | 0.206 | 0.65 | |||
| ≤ 60 | 98 | 51 (52.05) | 47 (47.95) | ||
| > 60 | 195 | 96 (49.24) | 99 (50.76) | ||
| Gender | 2.13 | 0.144 | |||
| Male | 138 | 63 (45.65) | 75 (54.35) | ||
| Female | 155 | 84 (54.19) | 71 (45.81) | ||
| TNM stage | 7.689 | 0.004* | |||
| I and II | 223 | 122 (54.70) | 101 (45.30) | ||
| III and IV | 70 | 25 (35.70) | 45 (64.30) | ||
| Tumor stage | 7.201 | 0.027* | |||
| I | 88 | 54 (61.40) | 34 (38.60) | ||
| II | 169 | 80 (47.30) | 89 (52.70) | ||
| III and IV | 37 | 14 (37.80) | 23 (62.20) | ||
| Metastasis stage | 2.809 | 0.094 | |||
| Negative | 274 | 141 (51.50) | 133 (48.50) | ||
| Positive | 19 | 6 (31.60) | 13 (68.40) | ||
| Node stage | 2.259 | 0.133 | |||
| Negative | 187 | 100 (53.50) | 87 (46.50) | ||
| Positive | 106 | 47 (44.30) | 59 (55.70) | ||
*Statistically significant